Research stack

CJC-1295 (no-DAC) + Ipamorelin Cutting Pulse

GHRH + GHRP pulse protocol used adjunctively during a caloric-deficit research protocol.

Component peptides

The short-acting variant of CJC-1295 — a GHRH(1-29) analog with four amino-acid substitutions for degradation resistance but without the maleimidopropionic-acid moiety that produces albumin binding. Half-life on the order of 30 minutes, in contrast to the DAC version's multi-day exposure.

Ipamorelin

A pentapeptide growth-hormone secretagogue that binds the ghrelin/GHS-R1a receptor, reported as one of the most selective GH-releasers with minimal effect on cortisol or prolactin.

Goal

GHRH + GHRP pulse protocol run during a caloric deficit.

Peptides

CJC-1295 (no-DAC), Ipamorelin

Why it works

Combined GHRH-analog and selective ghrelin-receptor agonism produce a larger synergistic GH pulse than either alone, biasing substrate use toward lipolysis while preserving endogenous pulsatility.

How to use

CJC-1295 (no-DAC) — 100 mcg per pulse, 2-3x daily subcutaneous.
Ipamorelin — 100-300 mcg per pulse, co-administered with the GHRH arm.

Last updated: 2026-09-15

Component peptides	CJC-1295 no DAC + Ipamorelin
Duration reported	12 weeks
Cycle pattern	12 weeks on, 4 weeks off
Difficulty	intermediate
Regulatory status	Research use only. None of these compounds is FDA-approved for combined use described.

Peptide Codex Assistant

Research-literature companion

Hello. Ask me about a peptide, a stack, or a research protocol on Peptide Codex.

0 / 20 questions used todayResearch use only. Not medical advice.